Avidity Partners Management portfolio
Concentrated managerInvestment firmPortfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 14, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Avidity Partners Management reported a $624M portfolio of 45 positions to the SEC as of the end of Q2 2026. Its largest positions are DNTH, CGON, ORKA. During the quarter it opened Senseonics Holdings.
Sections with a free account
What changed this quarter
49 positions with a change (3 new, 4 added to, 28 trimmed, 14 sold); also, 4 entered through an IPO. 12 are listed here: those of 0.5 points of the portfolio or more (up to 12).
- Newly listedMobia MedicalMOBI1.7% of the portfolio
It started trading this quarter: it appears in a 13F for the first time. The filing does not say whether the manager already held it before the listing, so it is not counted as a purchase.
- Dianthus Therapeutics−50%fewer sharesReduced38.6% → 32.8%
- Oruka Therapeutics−50%fewer sharesReduced9.5% → 11.6%
- Jade Biosciences−39%fewer sharesReduced5.8% → 6.1%
- Perspective Therapeutics−48%fewer sharesReduced5.2% → 3.4%
- Teva Pharmaceutical Industries−69%fewer sharesReduced2.2% → 1.1%
- Aktis Oncology−48%fewer sharesReduced1.8% → 2.5%
- Enliven Therapeutics−31%fewer sharesReduced3.4% → 4.5%
- Vir Biotechnology−67%fewer sharesReduced1.6% → 0.8%
- Palvella Therapeutics−50%fewer sharesReduced1.9% → 1.7%
- Repligen−50%fewer sharesReduced2.0% → 1.7%
- Medtronic−65%fewer sharesReduced1.8% → 0.9%
- Senseonics Holdings+1.0 ppof portfolioNew— → 1.5%
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- Dianthus TherapeuticsDNTH32.8%
- CG OncologyCGON15.9%
- Oruka TherapeuticsORKA11.6%
- Jade BiosciencesJBIO6.1%
- Enliven TherapeuticsELVN4.5%
- Perspective TherapeuticsCATX3.4%
- Aktis OncologyAKTS2.5%
- Palvella TherapeuticsPVLA1.7%
- Mobia MedicalMOBI1.7%
- RepligenRGEN1.7%
- ImmunicIMUX1.6%
- Senseonics HoldingsSENS1.5%
- Karyopharm TherapeuticsKPTI1.4%
- TEVA Pharmaceutical IndustriesTEVA1.1%
- DexcomDXCM1.1%
“Since”: first quarter of the current run, unbroken until today. In the details, prices are the quarter-end prices of the quarters in which it added shares, per the 13F. The manager may have bought at any price within each quarter; the SEC only publishes the value at quarter end.
Portfolio by sector
- ● Health Care 99%
- ● Information Technology 1%
How its portfolio changed (8 quarters)
Q2 2026: 45
Q2 2026: 82%
Q2 2026: 27.7%
Traded turnover: the weight it bought plus the weight it sold in the quarter, divided by two, excluding price moves. The plain “turnover” in the header does include that effect. With a free account: the full history and sectors over time.
13F filings with amendments or confidential positions
- 13F Q1 2026 ↗filed May 13, 2026Amendment of May 28, 2026 (adds holdings) ↗45 positions known later through an amendment, worth $494M: they could not be copied when the 13F was published.
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
How we classify it
Investment firm, per its Form ADV of Mar 31, 2026 (high confidence).
The data, as reported: AVIDITY PARTNERS MANAGEMENT LP (CRD 304628): 7.B private funds: 3 hedge (gross assets $1.1 bn); 5.D assets by client type: pooled vehicles 100% (of $1.1 bn) · 13F: 77% of the portfolio was already held when the stock started trading
The type comes from a rule applied to that data. If it looks wrong, tell us.
Similar managers by type and size
Same type of filer and a 13F portfolio value between a third and three times this one. It is not a comparison of what they hold.
- East Coast Asset ManagementInvestment firm · $624M
- Third Avenue ManagementInvestment firm · $625M
- Dudley & ShanleyInvestment firm · $629M
- Robert RobottiInvestment firm · $620M
- Lynrock LakeInvestment firm · $629M
- St. James InvestmentInvestment firm · $630M